newsfilter
← Latest News
GlobeNewswire·

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 4, 2026 in Aquestive Therapeutics, Inc. Lawsuit - AQST

  • The Gross Law Firm issued a shareholder notice for Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding a class action lawsuit.
  • The class period spans from June 16, 2025, to January 8, 2026.
  • The complaint alleges defendants made false or misleading statements while concealing material adverse facts regarding the New Drug Application (NDA) for Anaphylm.
  • Aquestive allegedly minimized the significance of human factors involved with the sublingual film, including packaging, use, administration, & labeling.
  • On January 9, 2026, the company received an FDA letter identifying deficiencies that prevented labeling discussions for Anaphylm.
  • The FDA confirmed the NDA review was ongoing with no final decision, delaying approval beyond the January 31, 2026 Prescription Drug User Fee Act deadline.
  • Following the January 9, 2026 announcement, AQST stock price dropped from $6.21 to $3.91 per share, a decline exceeding 37% in one day.
  • The deadline to register as a lead plaintiff is May 4, 2026.
  • Shareholders who register will be enrolled in portfolio monitoring software for case status updates.
  • There is no cost or obligation for shareholders to participate in this legal action.